Ophthotech Corporation
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Ophthotech Corporation |
Stock Symbol : | NASDAQ: OPHT |
Class Period Start: | 05/11/2015 |
Class Period End: | 12/12/2016 |
Lead Plaintiff motion: | 03/13/2017 |
Date Filed: | 01/11/2017 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Southern District of New York |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the March 13, 2017 lead plaintiff deadline in a class action lawsuit filed against Ophthotech Corporation (NASDAQ: OPHT) (“Ophthotech” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Ophthotech Corporation securities between May 11, 2015 and December 12, 2016, have until March 13, 2017 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Ophthotech Corporation securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Ophthotech misrepresented the effectiveness and potential of its of its treatment Fovista when used in combination with Lucentis, a anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. On December 12, 2016, the Company revealed results of the two pivotal phase 3 trials of Fovista disclosing that the treatment, administered in combination with Lucentis, had failed to achieve its primary endpoint of visual acuity at 12 months compared to Lucentis administered as a monotherapy under the guidelines established by the FDA. On this news, NASDAQ: OPHT dropped approximately 86% to close at $5.29. If you were negatively impacted by your investment in Ophthotech Corporation securities between May 11, 2015 and December 12, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |